The Journal of Thoracic and Cardiovascular Surgery

Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model

Retrieved on: 
Monday, October 16, 2023
Patent, HAV, Buddha's hand, The Journal of Thoracic and Cardiovascular Surgery, Research, Nationwide, CABG, Heart, Tetralogy of Fallot, Hospital, FDA, Nationwide Children's Hospital, Regenerative medicine, National Center for Regenerative Medicine, Tetralogy, HUMA, Peripheral artery disease, Child, Patient, Sale, Pharmaceutical industry, Dentistry

The publication in the open-access Journal of Thoracic and Cardiovascular Surgery (JTCVS Open), entitled “ Evaluation of tissue-engineered human acellular vessels as a Blalock–Taussig–Thomas shunt in a juvenile primate model, ” describes a preclinical study in which researchers from Humacyte and Nationwide Children's Hospital (Columbus, OH) implanted 3.5mm diameter HAVs into a juvenile large-animal model of pediatric heart disease.

Key Points: 
  • The publication in the open-access Journal of Thoracic and Cardiovascular Surgery (JTCVS Open), entitled “ Evaluation of tissue-engineered human acellular vessels as a Blalock–Taussig–Thomas shunt in a juvenile primate model, ” describes a preclinical study in which researchers from Humacyte and Nationwide Children's Hospital (Columbus, OH) implanted 3.5mm diameter HAVs into a juvenile large-animal model of pediatric heart disease.
  • The study assessed the HAV’s patency, structure, and blood flow from one week to six months after the implant.
  • This study also demonstrates the successful extension of Humacyte’s manufacturing platform, from the production of 6.0mm vessels to 3.5mm vessels.
  • The HAV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Abyrx Receives FDA Clearance for MONTAGE® Settable Bone Putty for Use in Cardiothoracic Surgery

Retrieved on: 
Tuesday, September 26, 2023
Ankle, Video-assisted thoracoscopic surgery, Partnership, Surgeon, University, Bleeding, Sternum, NCT, University of Calgary, Elective surgery, Libin Cardiovascular Institute, Anatomy, Foot, Bone wax, The Journal of Thoracic and Cardiovascular Surgery, Pain, Journal, MD, Patient, Nightfall and Other Stories, FDA, Trauma, Sports medicine, Safety, Flowable, Pharmaceutical industry, Dentistry, Medical device

STAMFORD, Conn., Sept. 26, 2023 /PRNewswire/ -- Abyrx, Inc. (http://abyrx.com), a leading biomaterial sciences company with a focus on therapeutic technologies for use during surgical procedures, today announced that the United States Food and Drug Administration (FDA) has provided regulatory clearance for the company's MONTAGE® Settable Bone Putty for use in cardiothoracic surgery following sternotomy. This represents the first time that the FDA has granted clearance for the use of a settable bone putty on the sternum, and it follows previous FDA clearances for MONTAGE as a bone void filler, cranial cement, and hemostatic bone putty.

Key Points: 
  • This represents the first time that the FDA has granted clearance for the use of a settable bone putty on the sternum, and it follows previous FDA clearances for MONTAGE as a bone void filler, cranial cement, and hemostatic bone putty.
  • MONTAGE is unique as a moldable putty that adheres to bleeding bone and rapidly hardens to achieve bone-like properties after application.
  • Upon application, MONTAGE controls bleeding and eliminates the need for topical agents known to prevent bone healing, such as bone wax.
  • For over a decade, Dr. Fedak has championed enhanced sternal closure using settable biomaterials to accelerate patient recovery after open heart surgery.

Surgery is facing its #MeToo moment – here's what needs to be done now

Retrieved on: 
Saturday, September 16, 2023
Male, Surgeon, Probability, General Medical Council, Prevalence, Life, Education, Health, Culture, Shock, Woman, The Journal of Thoracic and Cardiovascular Surgery, Comment, Assault, NHS, Research, Safety, Empowerment, Social media, Female, Nursing, Pharmaceutical industry, Guardian

Harrowing accounts of female doctors being sexually harassed, assaulted and even raped by their colleagues, highlight an urgent issue that must be addressed.

Key Points: 
  • Harrowing accounts of female doctors being sexually harassed, assaulted and even raped by their colleagues, highlight an urgent issue that must be addressed.
  • Such degrading acts have been openly shared across various platforms, notably on X (formerly Twitter), emphasising that they were not isolated occurrences.
  • The narratives shared across social media and news outlets underscore the fact that such misconduct is not limited to operating theatres.
  • In light of the troubling revelations about widespread sexual misconduct, the imperative is clear: decisive and immediate action is needed.

Concrete decree

    • Critically, this should not just be a buzzword but a concrete decree.
    • Trusts must make sure that they have policies in place, publicly available, which ensure that even the slightest misconduct will incur repercussions, ranging from suspension to legal consequences.
    • Creating a culture where people feel empowered to report incidents, backed by the assurance of collective support, is vital.

Active intervention

    • The answer lies in active intervention training.
    • It involves educating people to recognise inappropriate behaviour, feel empowered to act, adopt strategies to intervene constructively, shift from passive observation to active prevention, and foster a wider collective responsibility culture.
    • It can empower every one of us to identify and challenge inappropriate behaviour, fostering safer and more respectful communities for all.

Teleflex Receives FDA Clearance for Expanded Indication for QuikClot Control+™ Hemostatic Device Usage in Cardiac Surgical Procedures

Retrieved on: 
Tuesday, August 1, 2023
Video-assisted thoracoscopic surgery, Bleeding, Regulation of tobacco by the U.S. Food and Drug Administration, TFX, The Journal of Thoracic and Cardiovascular Surgery, Elective surgery, Journal, Hemostasis, Patient, IDE, FDA, NYSE, Safety, Medical device, Dentistry, Teleflex, Anesthesia, QuikClot

This allows clinicians to use the QuikClot Control+™ Device to control all bleeding in cardiac surgical procedures.

Key Points: 
  • This allows clinicians to use the QuikClot Control+™ Device to control all bleeding in cardiac surgical procedures.
  • The expanded indications enable device utilization across a wider patient population and breadth of surgical procedures.
  • The QuikClot Control+™ Hemostatic Device also received expanded intended uses to include use with patients on anticoagulation/antiplatelet medication, use with or without autotransfusion (blood salvage) equipment, and use with or without cardiopulmonary bypass systems.
  • “We look forward to supporting positive patient outcomes in these procedures through the expanded use potential of our QuikClot Control+™ Devices.”

Asia Pacific Leads the Growth in the Global Surgical Drainage Devices Market with the Fastest CAGR of 8.0% by 2030, Companies like Medtronic and Ethicon Focus on Diverse Product Offerings - ResearchAndMarkets.com

Retrieved on: 
Monday, July 24, 2023
General Health, Health, Surgery, Medical Devices, Infection, The Journal of Thoracic and Cardiovascular Surgery, Urbanization, Poverty, Surgeon, Prevalence, Thorax, COVID-19, USD, Hospital, Ill, Conditional sentence, FDA, Medical device, Dentistry, Orthopedic surgery

The global surgical drainage devices market size is expected to reach USD 4.04 billion by 2030, registering a CAGR of 6.4% from 2023 to 2030.

Key Points: 
  • The global surgical drainage devices market size is expected to reach USD 4.04 billion by 2030, registering a CAGR of 6.4% from 2023 to 2030.
  • This industry is growing due to the increasing rate of chronic diseases across the globe which often requires surgical intervention.
  • Additionally, there is a growing awareness among healthcare professionals about the importance of preventing surgical site infections, which has led to an increased demand for the high-quality surgical drainage devices.
  • However government initiatives had also ensured that patient and hospitals have access to quality medical devices access.

SS Innovations International Surgical Robotic System Successfully Completes Complex Cardiac Surgery

Retrieved on: 
Tuesday, June 13, 2023
CE, Medicine, CDSCO, Mantra, OTC Markets Group, TECAB, The Journal of Thoracic and Cardiovascular Surgery, SSI, Elective surgery, Journal, Patient, Narayana Health, OTC, Narayana Institute of Cardiac Sciences, FDA, Hospital, Medical device

FORT LAUDERDALE, FL, June 13, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announces the successful completion of two cardiac surgical procedures utilizing the company’s SSi Mantra surgical robotic system.

Key Points: 
  • FORT LAUDERDALE, FL, June 13, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announces the successful completion of two cardiac surgical procedures utilizing the company’s SSi Mantra surgical robotic system.
  • The two adult coronary artery bypass procedures were performed by Dr. Sudhir Srivastava , CEO, Chairman and Founder of SS Innovations, and  Dr. Nitin Rajput, Senior Consultant Cardiac Surgery at  Narayana Health.
  • Dr. Srivastava said, “SS Innovations is committed to improving access for patients and optimizing surgical outcomes with our accessible and cost-effective surgical system, the SSi Mantra.
  • In May 2023, Dr. Srivastava performed an additional robotic cardiac surgery using the SSi Mantra Surgical Robotic System at Continental Hospitals, Hyderabad.

Global Intraoperative Neuromonitoring Market Expected to Surpass $3,413.0 Million, at 4.5% CAGR from 2019 to 2026 [120-Pages] | Clarified by Research Dive

Retrieved on: 
Monday, March 27, 2023
The Journal of Thoracic and Cardiovascular Surgery, ENT, Orthopedic surgery, Minimally invasive spine surgery, Neuro, Patient, Investment, Conditional sentence, Growth, Knowledge, Center for Urban and Regional Analysis, Research, Pet industry, Medical device

NEW YORK, March 27, 2023 /PRNewswire/ -- Research Dive has added a new report to its offering titled, "Intraoperative Neuromonitoring Market, by Monitoring Type (Insourced Monitoring, Outsourced Monitoring), Application (Neuro & Spine Surgeries, Cardiovascular Surgeries, ENT Surgeries, and Orthopedic Surgeries), Regional Analysis (North America, Europe, Asia-Pacific, LAMEA): Global Opportunity Analysis and Industry Forecast, 2019-2026".

Key Points: 
  • Increasing use of intraoperative neuromonitoring devices in several surgeries is fueling the global intraoperative neuromonitoring market growth in the 2019-2026 timeframe.
  • The global intraoperative neuromonitoring market is projected to exceed $3,413.0 million by 2026, rising at a CAGR of 4.5% in the 2019–2026 timeframe.
  • The prime factor boosting the growth of the global intraoperative neuromonitoring market is the increasing cases of chronic diseases and rising usage of intraoperative neuromonitoring devices in several surgeries like orthopaedic, ENT, and others.
  • However, the lack of professionals having knowledge of intraoperative neuromonitoring devices and high costs involved in the surgeries using such devices are anticipated to hinder the market growth in the estimated timeframe.

Global Intraoperative Neuromonitoring Market Expected to Surpass $3,413.0 Million, at 4.5% CAGR from 2019 to 2026 [120-Pages] | Clarified by Research Dive

Retrieved on: 
Monday, March 27, 2023
The Journal of Thoracic and Cardiovascular Surgery, ENT, Orthopedic surgery, Minimally invasive spine surgery, Neuro, Patient, Investment, Conditional sentence, Growth, Knowledge, Center for Urban and Regional Analysis, Research, Pet industry, Medical device

NEW YORK, March 27, 2023 /PRNewswire/ -- Research Dive has added a new report to its offering titled, "Intraoperative Neuromonitoring Market, by Monitoring Type (Insourced Monitoring, Outsourced Monitoring), Application (Neuro & Spine Surgeries, Cardiovascular Surgeries, ENT Surgeries, and Orthopedic Surgeries), Regional Analysis (North America, Europe, Asia-Pacific, LAMEA): Global Opportunity Analysis and Industry Forecast, 2019-2026".

Key Points: 
  • Increasing use of intraoperative neuromonitoring devices in several surgeries is fueling the global intraoperative neuromonitoring market growth in the 2019-2026 timeframe.
  • The global intraoperative neuromonitoring market is projected to exceed $3,413.0 million by 2026, rising at a CAGR of 4.5% in the 2019–2026 timeframe.
  • The prime factor boosting the growth of the global intraoperative neuromonitoring market is the increasing cases of chronic diseases and rising usage of intraoperative neuromonitoring devices in several surgeries like orthopaedic, ENT, and others.
  • However, the lack of professionals having knowledge of intraoperative neuromonitoring devices and high costs involved in the surgeries using such devices are anticipated to hinder the market growth in the estimated timeframe.

Fountain Life Appoints Rakesh M. Suri, M.D., D.Phil., as President and Chief Medical Officer

Retrieved on: 
Thursday, October 13, 2022
Physician, Health, Editorial board, LinkedIn, Magdalen College, Oxford, Disease, Mayo Clinic, Queen's University, Life, Holm–Bonferroni method, American Board of Commissioners for Foreign Missions, The Journal of Thoracic and Cardiovascular Surgery, General surgery, Family, Longevity, Research, Instagram, American Board of Thoracic Surgery, Division, Queen, Facebook, Technology, Cancer, University, Cleveland, CEO, Cleveland Clinic, Journal, Artificial intelligence, Mayo College, Tesco international operations, FDA, Cardiothoracic surgery, Harvard Business School, Pharmaceutical industry

NAPLES, Fla., Oct. 13, 2022 /PRNewswire/ -- Fountain Life, a preventative health and longevity company committed to transforming global healthcare from reactive to proactive, today announced the appointment of Rakesh M. Suri, M.D., D.Phil., as the company's first President and Chief Medical Officer. Dr. Suri is an accomplished cardiac surgeon and prior executive leader at the Cleveland Clinic. In this new role, he will focus on the domestic and global expansion of Fountain Life's operations, including the establishment of partnerships with payers, community developers, corporate entities and wellness-oriented businesses. The mission of Fountain Life is to bring state-of-the-art diagnostics to detect disease early and to optimize and track the health of members in an experience-focused, technology-enabled and provider-led medical setting.

Key Points: 
  • The mission of Fountain Life is to bring state-of-the-art diagnostics to detect disease early and to optimize and track the health of members in an experience-focused, technology-enabled and provider-led medical setting.
  • "Fountain Life is a growing company that aims to transform healthcare through innovative data-driven technologies that help diagnose illnesses at their earliest stages," said William Kapp, M.D., Fountain Life's CEO and co-founder.
  • Before joining Fountain Life, Dr. Suri was President of International Operations and a practicing cardiothoracic surgeon at Cleveland Clinic in Ohio.
  • Fountain Life brings together the world's most renowned scientists and physicians to boost longevity and performance putting health back in healthcare.

CytoSorbents Reports New Cardiac Surgery Data with CytoSorb at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting

Retrieved on: 
Wednesday, October 12, 2022
EuroSCORE, Risk, Population, Infection, NASDAQ, Patient, Control, IV, Annual general meeting, Inflammation, Subclinical infection, The Journal of Thoracic and Cardiovascular Surgery, University, Infective endocarditis, Endocarditis, Cytokine adsorbing column, Association, Heart failure, Incidence, European Association for Cardio-Thoracic Surgery, Heart valve, Cytosorbents Corporation, SAE, Staphylococcus, Pharmaceutical industry, Dentistry

CytoSorb is used in this patient population during open heart surgery to control cytokine storm, reduce inflammation and Staphylococcal toxins, and reverse shock.

Key Points: 
  • CytoSorb is used in this patient population during open heart surgery to control cytokine storm, reduce inflammation and Staphylococcal toxins, and reverse shock.
  • Study population: 130 consecutive patients with confirmed SAE who underwent heart valve surgery at 2 leading German Heart Centers between 01/2015 03/2022.
  • Endre Nmeth (Budapest, Hungary) presented the results of the first ever randomized, controlled trial (RCT) using CytoSorb intraoperatively during cardiac transplantation.
  • CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification.